Ralf Illing: Proud to Contribute My Patient Voice to OCEANIC-STROKE Research
Ralf Illing, Program and Solution Manager, Data and Systems Integration, STO at GE Healthcare, shared on LinkedIn about a recent article he contributed to, adding:
”Proud to share that I contributed as a patient author to a peer-reviewed publication in Future Neurology:
‘Plain language summary of publication of the OCEANIC-STROKE Phase 3 study design: evaluating asundexian for preventing secondary strokes’
Sharma, Illing et al. | Future Neurology, 21(1), 2026
OCEANIC-STROKE is a global Phase 3 clinical trial involving approximately 12,300 participants across 37 countries, investigating whether asundexian – an oral Factor XIa inhibitor – can reduce the risk of secondary stroke when added to standard antiplatelet therapy, with minimal impact on bleeding risk.
As a stroke survivor myself, I was invited to co-author this plain language summary – a format designed to make complex clinical research accessible to patients, caregivers, and non-specialist healthcare providers.
Why does this matter?
Clinical trials generate critical evidence. But that evidence only creates real-world impact when patients and their families can actually understand it.
Plain language summaries bridge that gap – and patient authors help ensure the language truly reflects lived experience.
I believe that meaningful patient involvement in research – not just as participants, but as contributors and communicators – is essential for advancing patient-centered medicine.
The full results of OCEANIC-STROKE are yet to be published.
I look forward to seeing what they mean for the stroke community.”
Title: Plain language summary of publication of the OCEANIC-STROKE Phase 3 study design: evaluating asundexian for preventing secondary strokes
Authors: Mukul Sharma, Ralf Illing, Pablo Colorado, Jennifer Gilbride, Lars Keller, Eva Muehlhofer, Ashkan Shoamanesh
Read the Full Article on Future Neurology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 15:38Hugo Antonio Romo Rubio: ASH ISTH 2026 Guidelines on Prophylactic Anticoagulation In Pediatrics
-
Apr 12, 2026, 15:26Melissa Lewellyn: The DVT and PE Awareness Resolution from NBCA Is Now Live
-
Apr 12, 2026, 14:58Akram Shibani: HI-PEITHO Trial Reminds Us Why Composite Endpoints Deserve Careful Scrutiny
-
Apr 12, 2026, 14:493 Days, 14 Leaders, 1 Mission at The 13th EHC Youth Leadership Workshop
-
Apr 12, 2026, 14:27Moustafa Abdou: Paroxysmal Nocturnal Hemoglobinuria From a Rare Disease to a Treatable Condition
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen